The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
S100P Stimulates Cell Proliferation and Survival via Receptor for Activated Glycation End Products (RAGE)
Open accessAbstract
S100P is a member of the S100 protein family that is expressed in several malignant neoplasms. Currently the effects of this molecule on cell function are unknown. In the present study we investigated the biological effects and mechanisms of action of S100P using NIH3T3 cells. Expression of S100P in NIH3T3 cells led to the presence of S100P in the culture medium, increased cellular proliferation, and enhanced survival after detachment from the culture substrate or after exposure to the chemotherapeutic agent 5-flurouracil. The proliferation and survival effects of S100P expression were duplicated in a time- and concentration-dependent manner by the extracellular addition of purified S100P to wild-type NIH3T3 cells and correlated with the activation of extracellular-regulated kinases (Erks) and NF-kappaB. To determine the mechanisms involved in these effects, we tested the hypothesis that S100P activated RAGE (receptor for activated glycation end products). We found that S100P co-immunoprecipitated with RAGE. Furthermore, the effects of S100P on cell signaling, proliferation, and survival were blocked by agents that interfere with RAGE including administration of an amphoterin-derived peptide known to antagonize RAGE activation, anti-RAGE antibodies, and by expression of a dominant negative RAGE. These data suggest that S100P can act in an autocrine manner via RAGE to stimulate cell proliferation and survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene-expression profiles predict survival of patients with lung adenocarcinoma
Beer, D. G., Kardia, S. L. R., Huang, C.-C., Giordano, T. J., Levin, A. M., Misek, D. E., Lin, L., Chen, G., Gharib, T. G., Thomas, D. G., et al. (2002) · Nature Medicine · doi:10.1038/nm733 · Cited by 2,025
RAGE Mediates a Novel Proinflammatory Axis
Hofmann, M. A., Drury, S., Fu, C., Qu, W., Taguchi, A., Lu, Y., Avila, C., Kambham, N., Bierhaus, A., Nawroth, P., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80801-6 · Cited by 1,864
Self-citationDonato, R. (2001) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00046-2 · Cited by 1,580
The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses
Schmidt, A. M., Yan, S. D., Yan, S. F., & Stern, D. M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14002 · Cited by 1,253
Self-citationBlockade of RAGE-amphoterin signalling suppresses tumour growth and metastases
Taguchi, A., Blood, D. C., del Toro, G., Canet, A., Lee, D. C., Qu, W., Tanji, N., Lu, Y., Lalla, E., Fu, C., et al. (2000) · Nature · doi:10.1038/35012626 · Cited by 1,217
Self-citationThe S100 family of EF-hand calcium-binding proteins: functions and pathology
SCHAFER, B. (1996) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(96)10020-7 · Cited by 999
Intracellular and extracellular roles of S100 proteins
Donato, R. (2003) · Microscopy Research and Technique · doi:10.1002/jemt.10296 · Cited by 974
The S100 protein family: History, function, and expression
Zimmer, D. B., Cornwall, E. H., Landar, A., & Song, W. (1995) · Brain Research Bulletin · doi:10.1016/0361-9230(95)00040-2 · Cited by 927
Diabetes-Associated Sustained Activation of the Transcription Factor Nuclear Factor-κB
Bierhaus, A., Schiekofer, S., Schwaninger, M., Andrassy, M., Humpert, P. M., Chen, J., Hong, M., Luther, T., Henle, T., Klöting, I., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.12.2792 · Cited by 824
Self-citationLander, H. M., Tauras, J. M., Ogiste, J. S., Hori, O., Moss, R. A., & Schmidt, A. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.28.17810 · Cited by 813
Self-citation
Cited by
Marenholz, I., Heizmann, C. W., & Fritz, G. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.07.096 · Cited by 848
Ramasamy, R., Vannucci, S. J., Yan, S. S. D., Herold, K., Yan, S. F., & Schmidt, A. M. (2005) · Glycobiology · doi:10.1093/glycob/cwi053 · Cited by 834
Self-citationBresnick, A. R., Weber, D. J., & Zimmer, D. B. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3893 · Cited by 822
Sparvero, L. J., Asafu-Adjei, D., Kang, R., Tang, D., Amin, N., Im, J., Rutledge, R., Lin, B., Amoscato, A. A., Zeh, H. J., et al. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-17 · Cited by 622
Calcium-dependent and -independent interactions of the S100 protein family
Santamaria-Kisiel, L., Rintala-Dempsey, A. C., & Shaw, G. S. (2006) · Biochemical Journal · doi:10.1042/bj20060195 · Cited by 581
Alarmins: awaiting a clinical response
Chan, J. K., Roth, J., Oppenheim, J. J., Tracey, K. J., Vogl, T., Feldmann, M., Horwood, N., & Nanchahal, J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62423 · Cited by 511
Binding of S100 proteins to RAGE: An update
Leclerc, E., Fritz, G., Vetter, S. W., & Heizmann, C. W. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.11.016 · Cited by 489
Advanced glycation end products and the kidney
Bohlender, J. M., Franke, S., Stein, G., & Wolf, G. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00398.2004 · Cited by 387
Masquerader: High Mobility Group Box-1 and Cancer
Ellerman, J. E., Brown, C. K., de Vera, M., Zeh, H. J., Billiar, T., Rubartelli, A., & Lotze, M. T. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1953 · Cited by 355
Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation
Foell, D., Frosch, M., Sorg, C., & Roth, J. (2004) · Clinica Chimica Acta · doi:10.1016/j.cccn.2004.02.023 · Cited by 314
Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective
Bongarzone, S., Savickas, V., Luzi, F., & Gee, A. D. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00058 · Cited by 313
Ghavami, S., Rashedi, I., Dattilo, B. M., Eshraghi, M., Chazin, W. J., Hashemi, M., Wesselborg, S., Kerkhoff, C., & Los, M. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0607397 · Cited by 310
RAGE: therapeutic target and biomarker of the inflammatory response—the evidence mounts
Ramasamy, R., Yan, S. F., & Schmidt, A. M. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0409230 · Cited by 283
Self-citationHERMANI, A., DESERVI, B., MEDUNJANIN, S., TESSIER, P., & MAYER, D. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.10.013 · Cited by 262
Unlocking the biology of RAGE in diabetic microvascular complications
Manigrasso, M. B., Juranek, J., Ramasamy, R., & Schmidt, A. M. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.08.002 · Cited by 209
Self-citationArumugam, T., Ramachandran, V., & Logsdon, C. D. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj498 · Cited by 159
Self-citationS100P-Derived RAGE Antagonistic Peptide Reduces Tumor Growth and Metastasis
Arumugam, T., Ramachandran, V., Gomez, S. B., Schmidt, A. M., & Logsdon, C. D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0221 · Cited by 167
“S100P, S100A4, and HMGB-1–binding study Recombinant S100P (14), S100A4, and HMGB-1 proteins (R&D Systems), S100P monoclonal antibody (R&D Systems), S100A4 and HMGB-1 antibody (Abcam), and an ELISA kit (KPL) were used in to develop an ELISAbased assay to determine the binding of S100P with its receptor RAGE.”
Self-citationS100P: a novel therapeutic target for cancer
Arumugam, T., & Logsdon, C. D. (2011) · Amino Acids · doi:10.1007/s00726-010-0496-4 · Cited by 125
Self-citation
Metadata
- Authors
- Arumugam, T., Simeone, D. M., Schmidt, A. M., & Logsdon, C. D.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-02
- Volume
- 279
- Issue
- 7
- Pages
- 5059-5065
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2003421056
- Cited by
- 267
- References
- 34
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.